A Phase 3 interventional study of Secukinumab in Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-17.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 29th largest by enrollment, is one of 7 that started in 2015, is one of 24 in phase 3, and was the 24th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 7 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 34th largest by enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2015, is one of 30 in phase 3, and was the 33rd registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered subcutaneously during 52 weeks (plus extension) in patients with moderate to severe psoriasis.
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
Drug: Secukinumab
weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
Also known as: open label, no other intervention
proSPI (s) at Week 16 Compared to Baseline
The primary efficacy outcome of this study evaluates the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed for the purpose of this study.
Time frame: Week 0 (baseline) to 16 weeks
Changes of saSPI (s) at Week 16 Compared to Baseline
The primary efficacy objective of the study was to evaluate the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed. proSPI (s) score range is 0 to 50. Higher score means worse condition
Time frame: Week 0 (baseline) to 16 weeks
PASI (Psoriasis Area Severity Index) Score
PASI administered by a professional score range: 0 (no disease) to 72 (maximal disease)
Time frame: week 0, 16, 52
Correlation Between PASI and proSPI (s)
Psoriasis Area Severity Index vs Professional Version of Simplified Psoraisis Index (proSPI) score
Time frame: week 0, 16, 52
proSPI (s, p and i) Over Time
Professional Version of Simplified Psoriasis Index (proSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure
Time frame: weeks 0, 16, 52
saSPI (s, p and i) Over Time
Self-administered Simplified Psoriasis Index (saSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure
Time frame: weeks 0, 16, 52
DLQI (Dermatology Life Quality Index) Over Time
DLQI score has a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired MEANING OF DLQI SCORES 0 - 1 no effect on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life
Time frame: weeks 0, 16, 52
Self-administered PASI (SA-PASI)
self-administered PASI (SA-PASI) score
Time frame: weeks 0, 16, 52
Psoriasis Symptom Diary (PSD) Score
assessment of pain, itching and scaling using the Psoriasis Symptom Diary questionnaire over time PSD scores range from 0 to 10, with higher scores indicating a worse condition for each assessment: pain, itching and scaling
Time frame: weeks 0, 16, 52
Correlation Between proSPI (for Each Component: s, p and i) and DLQI
Correlation between proSPI (for each component: s, p and i) and DLQI is summarized in table below
Time frame: weeks 0, 16, 52
Correlation Between proSPI (for Components p and i) and PASI
Correlation between proSPI (p, i) and PASI score by visit (Full Analysis Set (observed)) is summarized in table below
Time frame: Over time (from Week 0 to Week 52)
Study centers: This study involved 17 active centers who enrolled (or recruited) patients in France First patient enrolled: 20-May-2015 Last patient completed: 09-Feb-2017
| Milestone | Single Arm Secukinumab |
|---|---|
| Started | 120 |
| Completed | 100 |
| Not completed | 20 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Physician decision | 2 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lack of efficacy | 7 |
The primary efficacy outcome of this study evaluates the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed for the purpose of this study.
| scores on a scale | Single Arm Secukinumab |
|---|---|
| W0 | 24.89 ± 10.747 |
| W16 | 2.34 ± 6.144 |
PASI administered by a professional score range: 0 (no disease) to 72 (maximal disease)
| scores on a scale | Single Arm Secukinumab |
|---|---|
| W0 | 23.09 ± 10.541 |
| W16 | 2.23 ± 3.927 |
| W52 | 3.16 ± 5.427 |
Psoriasis Area Severity Index vs Professional Version of Simplified Psoraisis Index (proSPI) score
| Spearman Correlation coefficient | Single Arm Secukinumab |
|---|---|
| W0 | 0.691 (0.58 to 0.78) |
| W16 | 0.814 (0.74 to 0.87) |
| W52 | 0.927 (0.89 to 0.95) |
Professional Version of Simplified Psoriasis Index (proSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure
| scores on a scale | Single Arm Secukinumab |
|---|---|
| proSPI (s) - W0 | 24.89 ± 10.747 |
| proSPI (s) - W16 | 1.83 ± 4.427 |
| proSPI (s) - W52 | 2.93 ± 6.557 |
| proSPI (p) - W0 | 7.80 ± 1.885 |
| proSPI (p) - W16 | 1.34 ± 2.201 |
| proSPI (p) - W52 | 1.59 ± 2.341 |
| proSPI (i) - W0 | 4.26 ± 1.924 |
| proSPI (i) - W16 | 4.78 ± 1.633 |
| proSPI (i) - W52 | 4.67 ± 1.613 |
Self-administered Simplified Psoriasis Index (saSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure
| saSPI score | Single Arm Secukinumab |
|---|---|
| saSPI(s) - W0 | 23.54 ± 10.412 |
| saSPI(s) - W16 | 1.80 ± 4.319 |
| saSPI(s) - W52 | 2.15 ± 4.229 |
| saSPI(p) - W0 | 8.18 ± 1.855 |
| saSPI(p) - W16 | 1.54 ± 2.299 |
| saSPI(p) - W52 | 1.47 ± 2.126 |
| saSPI(i) - W0 | 4.34 ± 1.940 |
| saSPI(i) - W16 | 4.39 ± 2.221 |
| saSPI(i) - W52 | 4.33 ± 2.276 |
DLQI score has a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired MEANING OF DLQI SCORES 0 - 1 no effect on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life
| DLQI score (range : 0 - 30) | Single Arm Secukinumab |
|---|---|
| WO | 13.6 ± 7.44 |
| W16 | 2.1 ± 3.67 |
| W52 | 1.9 ± 3.37 |
self-administered PASI (SA-PASI) score
| saPASI score (range: 0 to 72) | Single Arm Secukinumab |
|---|---|
| WO | 25.8 ± 13.55 |
| W16 | 2.6 ± 6.66 |
| W52 | 3.3 ± 7.10 |
assessment of pain, itching and scaling using the Psoriasis Symptom Diary questionnaire over time PSD scores range from 0 to 10, with higher scores indicating a worse condition for each assessment: pain, itching and scaling
| scores on a scale | Single Arm Secukinumab |
|---|---|
| Intensity of pain recorded in PSD- W0 | 5.2 ± 3.18 |
| Intensity of pain recorded in PSD - W16 | 0.9 ± 2.00 |
| Intensity of pain recorded in PSD - W52 | 0.9 ± 1.78 |
| Intensity of itching recorded in PSD - W0 | 6.7 ± 2.85 |
| Intensity of itching recorded in PSD - W16 | 1.3 ± 2.21 |
| Intensity of itching recorded in PSD - W52 | 1.4 ± 2.11 |
| Intensity of scaling recorded in PSD - W0 | 6.5 ± 2.70 |
| Intensity of scaling recorded in PSD - W16 | 1.0 ± 1.96 |
| Intensity of scaling recorded in PSD - W52 | 1.3 ± 2.00 |
Correlation between proSPI (for each component: s, p and i) and DLQI is summarized in table below
| Spearman correlation coefficient | Single Arm Secukinumab |
|---|---|
| proSPI (s) and DLQI - W0 | 0.224 (0.04 to 0.39) |
| proSPI (s) and DLQI - W16 | 0.418 (0.25 to 0.56) |
| proSPI (s) and DLQI - W52 | 0.514 (0.34 to 0.65) |
| proSPI (p) and DLQI - W0 | 0.494 (0.34 to 0.62) |
| proSPI (p) and DLQI - W16 | 0.671 (0.55 to 0.76) |
| proSPI (p) and DLQI - W52 | 0.757 (0.65 to 0.83) |
| proSPI (i) and DLQI - W0 | 0.102 (-0.08 to 0.28) |
| proSPI (i) and DLQI - W16 | 0.016 (-0.17 to 0.20) |
| proSPI (i) and DLQI - W52 | 0.131 (-0.08 to 0.33) |
Correlation between proSPI (p, i) and PASI score by visit (Full Analysis Set (observed)) is summarized in table below
| Spearman correlation coefficient | Single Arm Secukinumab |
|---|---|
| proSPI (p) and PASI - W0 | 0.173 (-0.01 to 0.34) |
| proSPI (p) and PASI - W16 | 0.678 (0.56 to 0.77) |
| proSPI (p) and PASI - W52 | 0.749 (0.64 to 0.83) |
| proSPI (i) and PASI - W0 | 0.014 (-0.17 to 0.19) |
| proSPI (i) and PASI - W16 | 0.105 (-0.08 to 0.29) |
| proSPI (i) and PASI - W52 | 0.172 (-0.04 to 0.36) |
The primary efficacy objective of the study was to evaluate the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed. proSPI (s) score range is 0 to 50. Higher score means worse condition
| scores on a scale | Single Arm Secukinumab |
|---|---|
| W0 | 23.54 ± 10.412 |
| W16 | 1.99 ± 4.508 |
Collected over baseline to 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 300mg | 2/120 (1.7%) | 13/120 (10.8%) | 86/120 (71.7%) |
| Event | AIN457 300mg |
|---|---|
| Coronary artery occlusionCardiac disorders | 1/120 |
| Punctate keratitisEye disorders | 1/120 |
| StomatitisGastrointestinal disorders | 1/120 |
| Strangulated umbilical herniaGastrointestinal disorders | 1/120 |
| Face oedemaGeneral disorders | 1/120 |
| Head injuryInjury, poisoning and procedural complications | 1/120 |
| Meniscus injuryInjury, poisoning and procedural complications | 1/120 |
| Tendon ruptureInjury, poisoning and procedural complications | 1/120 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/120 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/120 |
| Event | AIN457 300mg |
|---|---|
| NasopharyngitisInfections and infestations | 13/120 |
| Back painMusculoskeletal and connective tissue disorders | 13/120 |
| DiarrhoeaGastrointestinal disorders | 12/120 |
| BronchitisInfections and infestations | 11/120 |
| RhinitisInfections and infestations | 11/120 |
| PsoriasisSkin and subcutaneous tissue disorders | 11/120 |
| AstheniaGeneral disorders | 10/120 |
| InfluenzaInfections and infestations | 10/120 |
| HeadacheNervous system disorders | 9/120 |
| HypertensionVascular disorders | 9/120 |
FAS
| Age, Continuous(years) | Single Arm Secukinumab |
|---|---|
| Mean | 45.9 ± 14.17 |
| Sex: Female, Male(Participants) | Single Arm Secukinumab |
|---|---|
| Female | 37 |
| Male | 83 |
| Race (NIH/OMB)(Participants) | Single Arm Secukinumab |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 1 |
| White | 116 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| proSPI (s)(scores on a scale) | Single Arm Secukinumab |
|---|---|
| Mean | 24.9 ± 10.71 |
| saSPI (s)(score on a scale for each domain of SPI) | Single Arm Secukinumab |
|---|---|
| Mean | 23.5 ± 10.37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from May 2015 to primary completion in Feb 2017, 20 months.
Results were first posted in Apr 2019, 2 years 2 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 20 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab